Blog
RSS FeedPosted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
Posted by Michael Wonder on 26 May 2022
NICE recommends Libtayo (cemiplimab) for routine NHS commissioning as the first and only systemic treatment for advanced CSCC in England
25 May 2022 - NICE has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab) as the first and only ...
Posted by Michael Wonder on 25 May 2022
New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE
25 May 2022 - An estimated 100 people per year with triple negative breast cancer that has spread to other ...
Posted by Michael Wonder on 24 May 2022
NICE doesn’t recommend ibrutinib for those with Waldenstrom’s macroglobulinaemia
23 May 2022 - Ibrutinib, a drug used to treat Waldenström’s macroglobulinaemia, is not being recommended by NICE in England ...
Posted by Michael Wonder on 16 May 2022
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS
16 May 2022 - Durvalumab recommended as an option for treating non-small-cell lung cancer. ...
Posted by Michael Wonder on 14 May 2022
Hundreds of patients to get life-extending lung cancer drug on the NHS
13 May 2022 - Hundreds of people with a form of the most common form of lung cancer could survive ...
Posted by Michael Wonder on 11 May 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
11 May 2022 - NICE has published evidence based recommendations on the use of avelumab for adults with locally advanced ...
Posted by Michael Wonder on 27 Apr 2022
Tucatinib for adults with HER2 positive advanced breast cancer
27 April 2022 - NICE has published evidence-based recommendations on the use of tucatinib for the treatment of adults with ...
Posted by Michael Wonder on 27 Apr 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia
27 April 2022 - NICE has published evidence-based recommendations on the use of venetoclax in combination with low dose cytosine ...
Posted by Michael Wonder on 20 Apr 2022
NICE terminates appraisal of nivolumab
20 April 2022 - This is the first appraisal of nivolumab to be terminated by NICE. ...
Posted by Michael Wonder on 14 Apr 2022
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation
14 April 2022 - An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced ...
Posted by Michael Wonder on 14 Apr 2022
Alpelisib for patients with advanced hormone receptor positive, HER2 negative, PIK3CA mutated breast cancer
7 April 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 13 Apr 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
13 April 2022 - NICE has published evidence based recommendations on the use of daratumumab (Darzalex) for the treatment of ...
Posted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...